Drug news
Pivotal Study of E 2087 (Eisai) shows positive results in treating Epilepsy
A pivotal Phase III study of E 2087 (perampanel), from Eisai, developed as an adjunctive therapy for partial seizures in adult patients with Epilepsy, provides evidence that 4 and 8 mg/day doses of the drug are effective and well-tolerated in reducing uncontrolled partial-onset seizures when compared with placebo. Efficacy in seizure reduction was seen despite treatment with up to three other anti-epilepsy drugs. See: "Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures." G.L. Krauss et al. Neurology, April 18 2012 DOI: 10.1212/WNL.0b013e318254473
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.